Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Anti-Aging
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Medivir, GlaxoSmithKline enter co-promotion agreement
Stockholm, Sweden - Medivir has entered into a co-promotion agreement with the Swedish subsidiary of GlaxoSmithKline, according to Earthtimes.org.
Stockholm, Sweden
- Medivir has entered into a co-promotion agreement with the Swedish subsidiary of GlaxoSmithKline, according to Earthtimes.org.
The agreement will allow Medivir to co-promote some GlaxoSmithKline products on the Swedish market, such as the companies entire dermatology portfolio, including the eczema and psoriasis drug Betnovat.
The magnitude of revenue for Medivir is based on the degree that future sales exceed an agreed baseline, Earthtimes reports.
Related Videos
Related Content
